GE HealthCare Technologies Inc. Commences Secondary Offering of 13,281,302 Shares
GE HealthCare Technologies (Nasdaq: GEHC) announced a secondary public offering of 13,281,302 shares of common stock. The company will not sell any shares or receive proceeds from the offering. GE Aerospace plans to exchange these shares for debt held by Morgan Stanley Bank before the offering closes. Morgan Stanley & Co. will then sell the shares to underwriters. J.P. Morgan, Citigroup, and Morgan Stanley are serving as lead joint book-running managers for the offering.
GE HealthCare Technologies (Nasdaq: GEHC) ha annunciato un'offerta pubblica secondaria di 13.281.302 azioni ordinarie. L'azienda non venderà alcuna azione né riceverà proventi dall'offerta. GE Aerospace prevede di scambiare queste azioni per il debito detenuto da Morgan Stanley Bank prima della chiusura dell'offerta. Morgan Stanley & Co. venderà quindi le azioni ai sottoscrittori. J.P. Morgan, Citigroup e Morgan Stanley fungono da manager principali per l'offerta.
GE HealthCare Technologies (Nasdaq: GEHC) anunció una oferta pública secundaria de 13.281.302 acciones ordinarias. La empresa no venderá ninguna acción ni recibirá ingresos de la oferta. GE Aerospace planea canjear estas acciones por deuda mantenida por Morgan Stanley Bank antes de que cierre la oferta. Morgan Stanley & Co. venderá luego las acciones a los suscriptores. J.P. Morgan, Citigroup y Morgan Stanley están actuando como gerentes conjuntos principales para la oferta.
GE 헬스케어 테크놀로지스(Nasdaq: GEHC)는 13,281,302주 일반주식의 추가 공모를 발표했습니다. 회사는 어떠한 주식도 판매하지 않으며 공모에서 수익을 받지 않습니다. GE 항공우주는 공모가 종료되기 전에 이러한 주식을 모건 스탠리 은행이 보유한 채무와 교환할 계획입니다. 모건 스탠리 & Co.는 그 후 주식을 인수인에게 판매합니다. J.P. 모건, 씨티그룹, 모건 스탠리는 이 공모의 주요 공동 주간사로 활동하고 있습니다.
GE HealthCare Technologies (Nasdaq: GEHC) a annoncé une offre publique secondaire de 13.281.302 actions ordinaires. L'entreprise ne vendra aucune action et ne recevra aucun produit de l'offre. GE Aerospace prévoit d'échanger ces actions contre de la dette détenue par Morgan Stanley Bank avant la clôture de l'offre. Morgan Stanley & Co. vendra ensuite les actions aux souscripteurs. J.P. Morgan, Citigroup et Morgan Stanley agissent en tant que co-managers principaux pour l'offre.
GE HealthCare Technologies (Nasdaq: GEHC) hat eine sekundäre öffentliche Angebot von 13.281.302 Stammaktien angekündigt. Das Unternehmen wird keine Aktien verkaufen oder Erlöse aus dem Angebot erhalten. GE Aerospace plant, diese Aktien gegen Schulden, die von Morgan Stanley Bank gehalten werden, einzutauschen, bevor das Angebot schließt. Morgan Stanley & Co. wird dann die Aktien an die Underwriter verkaufen. J.P. Morgan, Citigroup und Morgan Stanley fungieren als leitende gemeinsame Buchmanager für das Angebot.
- None.
- Potential downward pressure on stock price due to large secondary offering of 13.28M shares
- Share dilution impact on existing stockholders
- Increased float may affect stock price stability
Insights
This secondary offering of 13.28 million shares represents a significant market event, though neutral for GE HealthCare as they won't receive proceeds. The transaction is effectively a debt reduction mechanism for GE Aerospace, converting their debt to equity which will then be sold to the market. With GEHC's current market cap of
The structure - where Morgan Stanley exchanges debt for equity before selling to the market - is a sophisticated approach to debt reduction that avoids direct market pressure that might come from GE Aerospace selling shares directly. The involvement of major underwriters (JPMorgan, Citigroup and Morgan Stanley) suggests strong institutional support for the offering, which should help maintain price stability during the distribution.
Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. (the “MS Lender”), an affiliate of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lender. Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriters in the Offering.
J.P. Morgan, Citigroup and Morgan Stanley are acting as the lead joint book-running managers for the Offering.
The Company has filed an automatically effective shelf registration statement (including a prospectus) on Form S-3 with the
This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a
Forward‐Looking Statements
This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the size, timing or results of the Offering and the selling stockholders’ intent to offer shares of common stock, and reflect management’s current plans, estimates and expectations and are inherently uncertain. The inclusion of any forward-looking information in this release should not be regarded as a representation that the future plans, estimates or expectations contemplated will be achieved. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause actual results to differ materially from those described in the Company’s forward-looking statements include, but are not limited to, operating in highly competitive markets; our ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the Company’s ability to operate effectively as an independent, publicly-traded company; and the other factors detailed in the Company’s Registration Statement on Form S-3 filed on February 15, 2024, as well as other risks discussed in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107213185/en/
Investor Relations:
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com
Media:
Jennifer Fox
+1-414-530-3027
jennifer.r.fox@gehealthcare.com
Source: GE HealthCare Technologies Inc.
FAQ
How many shares are being offered in GE HealthCare's (GEHC) secondary offering?
Will GE HealthCare (GEHC) receive any proceeds from the secondary offering?
Who are the lead underwriters for GE HealthCare's (GEHC) secondary offering?